CDMO
Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-24-CL-08Oct 11, 2024
CDMO
Wheeler Bio Licenses ATUM’s miFuc Technology to Expand Their Portable CMC Platform Capabilities
Wheeler Bio
PR-09-24-NI-14Sep 24, 2024
CDMO Model
Rethinking the Conventional CDMO Model
Wheeler Bio
PAO-08-24-CL-04Jul 29, 2024
Digitalization
Overcoming Development Challenges with Digital Solutions
Wheeler Bio
PAO-06-24-CL-06Jul 02, 2024
Leap-In Transposase
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Wheeler Bio
PAO-06-24-CL-05May 30, 2024
The PHASE Platform
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
Wheeler Bio
PAO-05-24-CL-01May 08, 2024
Commitment to ESG Principles
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Pharma's Almanac
PAO-03-24-CL-03Mar 08, 2024
Accelerating Product Development
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Pharma's Almanac
PAO-03-24-CL-02Mar 08, 2024
Portable CMC
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
Wheeler Bio
PR-M02-29-01Feb 29, 2024
CMC
Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform
Wheeler Bio
PAO-12-23-CL-04Feb 08, 2024
Supply Chain
Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience
Tim Tyson; Jesse McCool, Ph.D.; Russell Harris; Yongkwan Ma
TriRx Pharmaceutical Services
PTV-12-23-CL-02Dec 12, 2023
Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
Wheeler Bio
PR-M11-23-01Nov 08, 2023
Wheeler Bio Announces Grand Opening of Biomanufacturing Facility
Wheeler Bio
PR-M10-23-01Oct 05, 2023
Business Leadership
Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer
Wheeler Bio
PR-M08-23-01Aug 15, 2023
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05Jul 26, 2023
Leadership
Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer
Wheeler Bio
PR-M06-23-02Jun 06, 2023
Biologics Testing Lab
Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource℠ Laboratory
Wheeler Bio
PR-M06-23-01May 31, 2023
Cell Line Development Technology
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio
PR-M11-22-09Nov 30, 2022
Series A Funding
Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma
Wheeler Bio
PR-M10-22-02Oct 05, 2022
Leadership
Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer
Wheeler Bio
PR-M09-22-05Sep 22, 2022